The University of Arizona Wound Care Center Clinical Research Unit

项目摘要 大约25%的糖尿病患者患有糖尿病足溃疡（DFU）。这是一个重要的临床 问题是，由于没有有效的生物标志物来预测结果，最近没有候选药物 FDA已经批准，没有广泛有效的治疗方法。此外， 糖尿病和不愈合的DFU在少数民族中最高，如美洲原住民和西班牙裔 这一现象与社会贫困和高死亡率有关。 亚利桑那大学（UArizona）是美国西南部领先的公立研究型大学，也是一所 理想的跨学科研究社区研究DFU愈合。亚利桑那大学与 班纳健康去年为5,680名开放性伤口患者提供了服务。从外伤到足科， 在过去的3年里，Banner Health观察到3，770名糖尿病足溃疡（DFU）患者。Geoffrey Gurtner博士 在通过临床试验研究后期生物标志物验证方面有着悠久的历史， 通过收集大量高质量的生物样品，进行生物标志物的早期鉴定 纵向数据（目标1）。这是由亚利桑那大学的大量患者人群以及博士支持的。 Gurtner在从人类患者采集的DFU样本中鉴定速率细胞亚群的历史。 接下来，我们的目标是通过为DFU执行高质量的临床试验， 这在历史上一直很难招募，也通过收集高质量的数据，以解决 具有复杂病理、共病和社会因素的DFU的异质性。在亚利桑那大学， 和周博士进行高质量的临床试验，并获得广泛的患者分布和一系列的 确保“没有DFU患者未经研究”（目标2）的技术。接下来，我们多样化的患者库将允许 我们具体了解如何社会和环境背景因素（“健康的社会决定因素”; SDH）可能影响糖尿病愈合和生物标志物，特别是在多样化和广泛的患者中招募 池（目标3）。最后，我们不仅可以访问整个班纳健康网络（BHN），还可以访问印度 健康网络和拉丁美洲社区的外展计划。通过这个庞大的网络， 包括所有人口统计和社会经济地位的人，我们将建立有效的合作 在CRU和新的临床研究中心之间建立合作解决问题和高水平培训， 共享资源和价值（目标4）。

PROJECT SUMMARY Approximately 25% of diabetic patients experience diabetic foot ulcers (DFUs). This is a significant clinical problem since there are no effective biomarkers for predicting outcomes, no drug candidates that have recently been FDA-approved and no therapies that are widely effective in treatment. Additionally, the prevalence of diabetes and non-healing DFUs are highest among minorities, such as in Native American and Hispanic populations, and associated with social deprivation and high mortality. The University of Arizona (UArizona) is the leading public research university in the American Southwest and an ideal transdisciplinary research community for studying DFU healing. The partnership between UArizona and Banner Health provided service to 5,680 patients with open wounds last year. Ranging from trauma to podiatry, Banner Health saw 3,770 individuals with diabetic foot ulcers (DFUs) in the past 3 years. Dr. Geoffrey Gurtner has an established history in studying both late-stage biomarker validation through clinical trials and also mechanistic and early-stage biomarkers identification through the collection of many high-quality biosamples and longitudinal data (Aim 1). This is supported by both the large patient population at UArizona as well as Dr. Gurtner’s history in identifying rate cell subpopulations in DFU samples collected from human patients. Next, we aim to create a unified Standard of Care through the execution of high-quality clinical trials for DFUs, which historically have been difficult to recruit, and also by collecting high-quality data to address the heterogeneity of DFUs with complex pathologies, co-morbidities, and social factors. At UArizona, Dr. Gurtner and Dr. Zhou conduct high-quality clinical trials and have access to a wide distribution of patients and a range of techniques to make sure that “No DFU Patient Goes Unstudied” (Aim 2). Next, our diverse patient pool will allow us to specifically understand how social and environmental contextual factors (“social determinants of health”; SDH) may affect diabetic healing and biomarkers, specifically be recruiting over a diverse and expansive patient pool (Aim 3). Finally, we have access to not just the entire Banner Health Network (BHN), but also to the Indian Health Network and outreach programs for Latino communities. Through this expansive network that incorporates people of all demographics and socio-economic statuses, we will establish effective collaborations between the CRU and new clinical sites to generate cooperative problem-solving and high-level training, with shared resources and values (Aim 4).